

Bölüm 29

TİROİD MEDÜLLER KARSİNOM, ADRENAL GLAND NÖROENDOKRİN TÜMÖRLER, FEOKROMASİTOMA/ PARAGANGLİONOMADA CERRAHİ YAKLAŞIM

Cemil BİNARBAŞI³²

MEDÜLLER TİROİD KARSİNOMU

Giriş

Tiroid bezinin medüller karsinomu, tiroid bezinde folliküllerin etrafında yer alan parafoliküler C hücrelerinden köken almaktadır. Bu hücreler nöroendokrin sistemin üyesi olduğu için tiroid medüller karsinomu nöroendokrin tümör olarak kabul edilir. İlk defa Hazard ve arkadaşları tarafından 1959 yılında solid, follikül dışı histolojik özellikler, stromasında yüksek amiloid birikimi ve lenf nodlarına yüksek metastaz özelliği ile tanımlanmıştır. ¹

Parafoliküler C hücreler tiroid bezinin üst ve orta üçte birlik kısmında yoğunlaşmıştır. Bu hücreler özellikle kalsitonin sentezler. Ayrıca bu hücreler karsinoembryonik antijen, adrenokortikal uyarıcı hormon, histaminazlar, serotonin ve kromogranin sentezler. ^{2,3}

Tiroid bezinin medüller karsinomu tiroid bezi kanserleri arasında %5'lik kısmı oluşturur. Hastaların %75'i sporadik medüller karsinom iken %25'i herediter medüller karsinomdur. ⁴

Sporadik Medüller Tiroid Karsinomu

Sporadik medüller tiroid karsinomu genellikle 30-50'li yaşlarda görülür. ⁵

Tiroidde ele gelen nodül ile başvuran tiroid medüller karsinomu hastalarının %70'inde servikal metastazlar ve %10'nunda uzak organ metastazları görülür. 6 T1 tümörlerde santral ve lateral kompartman metastazları %11-14 oranında görülürken T4 tümörlerde %86-93 oranında görülür. ⁷

³² Uzm. Dr. Cemil Binarbaşı, Yenimahalle Eğitim ve Araştırma Hastanesi, Gastroenteroloji Cerrahisi, neodrasc@gmail.com

çevre dokulara ekilmesine ve lokal tümör nüksüne neden olabilir. Bu duruma paragangliomatosis veya feokromositomatosis adı verilir.

Hastaların kan glukozu da izlenir, çünkü dolaşımdaki katekolaminler azaldıkça postoperatif hipoglisemi oluşabilir.⁴⁸

Sonuç

Paraganglioma nadir görülen bir tümör olmasına rağmen, cerrahın hastayı tedavi için önceden hazırlanması gerekir. Preoperatif alfa blokajı ameliyat öncesi hazırlığın önemli bir parçasıdır ve bu tümörleri tanıyan endokrinologlarla işbirliği içinde yapılabilir. Nüks veya metastatik tümörü olan hastalar, bu hastalığın tedavisinde rahat olan multidisipliner bir ekip tarafından yönetilmelidir.

Anahtar Kelimeler: Medüller tiroid karsinomu, Feokromositoma, Paraganglioma

KAYNAKLAR

1. Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. *J Clin Endocrinol Metab.* 1959;19(1):152–61.
2. Abe K, Adachi I, Miyakawa S, Tanaka M, Yamaguchi K, Tanaka N, et al. Production of calcitonin, adrenocorticotrophic hormone, and beta-melanocyte-stimulating hormone in tumors derived from amine precursor uptake and decarboxylation cells. *Cancer Res.* 1977;37(11):4190–4.
3. Ishikawa N, Hamada S. Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. *Br J Cancer.* 1976;34(2):111–5
4. Cancer of the Thyroid Invasive: Trends in SEER Incidence and U.S. Mortality Using the Joinpoint Regression Program, 1975–2011(SEER)
5. Leboulleux S, Baudin E, Travagli JP, Schlumberger M 2004 Medullary thyroid carcinoma. *Clin Endocrinol* 61: 299–310.
6. Moley JF 2010 Medullary thyroid carcinoma: management of lymph node metastases. *J Natl Compr Canc Netw* 8:549–55
7. Machens A, Hinze R, Thomusch O, Dralle H 2002 Pattern of nodal metastasis for primary and reoperative thyroid cancer. *World J Surg* 26:22–28.
8. Steiner AL, Goodman AD, Powers SR 1968 Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. *Medicine (Baltimore)* 47:371–409.
9. Wermer P 1954 Genetic aspects of adenomatosis of endocrine glands. *Am J Med* 16:363–371
10. Pasini B, Hofstra RM, Yin L, Bocciardi R, Santamaria G, Grootsholten PM, et al. The physical map of the human RET protooncogene. *Oncogene.* 1995;11(9):1737–43.
11. Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T. Expression of the ret protooncogene product in human normal and neoplastic tissues of neural crest origin. *J Pathol.* 1994;172(3):255–60.
12. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET protooncogene are associated with MEN 2A and FMTC. *Hum Mol Genet.* 1993;2(7):851–6.
13. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in

- the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. *Nature*. 1994;367(6461):375–6.
14. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, et al. Somatic mutations in the RET protooncogene in sporadic medullary thyroid carcinoma. *Clin Endocrinol (Oxf)*. 1996;44(3):249–57
 15. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid*. 2015;25(6):567–610
 16. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid*. 2015;25(6):567–610.
 17. Machens A, Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. *World J Surg*. 2007;31(5):957–68.
 18. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid*. 2009;19(11):1167–214.
 19. Leboulleux S, Travagli JP, Caillou B, Laplanche A, Bidart JM, Schlumberger M, et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. *Cancer*. 2002;94(1):44–50
 20. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Hickey RC, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. *Medicine (Baltimore)*. 1984;63(6):319–42.
 21. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. *Cancer*. 2000;88(5):1139–48.
 22. Bugalho MJM, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. *J Surg Oncol*. 2005;91(1):56–60.
 23. Bhanot P, Yang J, Schnadig VJ, Logroño R. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature. *Diagn Cytopathol*. 2007;35(5):285–92.
 24. Forrest CH, Frost FA, de Boer WB, Spagnolo DV, Whitaker D, Sterrett BF. Medullary carcinoma of the thyroid: accuracy of diagnosis of fine-needle aspiration cytology. *Cancer*. 1998;84(5):295–302.
 25. Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. *Br J Surg*. 2008;95(5):586–91.
 26. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. *World J Surg*. 2007;31(10):1960–5.
 27. Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. *Surgery*. 2001;130(6):1044–9.
 28. Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. *World J Surg*. 2002;26(8):1023–8
 29. Lorenz K, Brauckhoff M, Behrmann C, Sekulla C, Ukkat J, Brauckhoff K, et al. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. *Surgery*. 2005;138(6):986–93. discussion 993
 30. Wertenbroek MWJLAE, Links TP, Prins TR, Plukker JTM, van der Jagt EJ, de Jong KP. Radiofrequency ablation of hepatic metastases from thyroid carcinoma. *Thyroid*. 2008;18(10):1105–10.

31. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S 2009 Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. *Nat Clin Pract Endocrinol Metab* 5:35–44.
32. Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. *J Nucl Med*. 2007;48(4):501–7.
33. Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. *J Clin Endocrinol Metab*. 2007;92(11):4185–90.
34. Manger WM. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. *Ann N Y Acad Sci*. 2006;1073:1–20.
35. Gimenez-Roqueplo A, Dahia P, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. *Horm Metab Res*. 2012;44:328–33.
36. Groeben H, Nottebaum BJ, Alesina PF, Traut A, Neumann HP, Walz MK. Perioperative α -receptor Pheochromocytoma blockade in pheochromocytoma surgery: an observational case series. *Br J Anaesth*. 2017;118(2):182–9.
37. Pacak K. Preoperative management of the pheochromocytoma patient. *J Clin Endocrinol Metab*. 2007;92:4069–79.
38. Thomas RM, Ruel E, Shantavasinkul PC, Corsino L. Endocrine hypertension: an overview on the current etiopathogenesis and management options. *World J Hypertens*. 2015;5(2):14–27.
39. Brandao LF, Autorino R, Laydner H, Haber G-P, Ouzaid I, Sio MD, Perdona S, Stein RJ, Porpiglia F, Kaouk JH. Robotic versus laparoscopic adrenalectomy: a systematic review and meta-analysis. *Eur Urol*. 2014;65:1154–61.
40. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2014;99:1915–42.
41. Hamidi O, Young WF Jr, Iniguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. *J Clin Endocrinol Metab*. 2017;102:3296–30
42. Kiernan CM, Solorzano CC. Pheochromocytoma and paraganglioma: diagnosis, genetics, and treatment. *Surg Oncol Clin N Am*. 2016;25:119–38.
43. Lenders JW, Eisenhofer G, Mannelli M, et al. Pheochromocytoma. *Lancet*. 2005;366:665–75.
44. Erlic Z, Rybicki L, Peczkowska M, et al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. *Clin Cancer Res*. 2009;15:6378–85.
45. Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. *J Intern Med*. 2009;266:43–52.
46. Benn DE, Robinson BG, Clifton-Bligh RJ. 15 YEARS OF PARAGANGLIOMA: clinical manifestations of paraganglioma syndromes types 1-5. *Endocr Relat Cancer*. 2015;22:T91–103
47. Chrisoulidou A, Kaltsas G, Ilias I, et al. The diagnosis and management of malignant pheochromocytoma and paraganglioma. *Endocr Relat Cancer*. 2007;14:569–85.
48. Chen Y, Hodin RA, Pandolfi C, et al. Hypoglycemia after resection of pheochromocytoma. *Surgery*. 2014;156:1404–8; discussion 1408–1409.